GlassScriptPhysician profile
Daniel J Rawlings
NPI 1457806275
$2,499.27
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,015 · 2023: $1,366 · 2024: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468 · Consulting Fee: $16.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.95 |
| Consulting Fee | $16.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $894.73 | 2022-2024 | Fasenra, Breztri, Tezspire |
| Genzyme Corporation | $543.94 | 2022-2024 | |
| Glaxosmithkline, LLC. | $192.52 | 2022-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $148.49 | 2022-2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $106.93 | 2022-2023 | Dupixent |
| Abbvie INC. | $96.46 | 2023 | |
| Csl Behring | $73.70 | 2022-2023 | Haegarda |
| Teva Pharmaceuticals USA, INC. | $65.98 | 2022-2023 | Airduo Digihaler |
| Optinose US, INC. | $63.54 | 2022-2023 | |
| Grifols USA, LLC | $59.82 | 2023 | Xembify, Prolastin-C Liquid |
| Kaleo, INC. | $55.63 | 2022-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.85 | 2023 | Spiriva Respimat, Spiriva |
| Mylan Specialty L.P. | $35.09 | 2023 | Yupelri |
| Biocryst US Sales Co., LLC | $29.20 | 2023 | Orladeyo |
| Blueprint Medicines Corporation | $27.69 | 2023 | Ayvakit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.10 | 2022 | |
| Leo Pharma INC. | $24.06 | 2024 | Adbry |
| Adma Biomanufacturing LLC | $16.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rawlings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.